Short-acting β2-agonists over-prescription in patients with asthma: an Indian subset analysis of international SABINA III study

The SABINA (SABA use IN Asthma) program was initiated to describe short-acting β2-agonists (SABA) prescription patterns and assess the impact of its over-prescription on exacerbation risk and asthma control. We evaluated SABA prescription patterns in patients with asthma in the Indian cohort of SABINA III. This multi-centre, observational, cross-sectional study included retrospective and real-time electronic data collection. Data were extracted from medical records of patients with asthma (aged >12 years) having >3 consultations with the same healthcare practitioners between March 2019 a... Mehr ...

Verfasser: Mahavir Modi (14264513)
Kavita Mody (14264516)
Pramod Jhawar (14264519)
Lata Sharma (14264522)
Mahesh Padukudru Anand (14264525)
Giriyanna Gowda (14264528)
Manisha Mendiratta (14264531)
Sudhir Kumar (26282)
Sandeep Nayar (14264534)
Manav Manchanda (14264537)
Aruna Kumari Badam (14264540)
Manoj Singh (90527)
Waseem Siddiqui (14264543)
Maarten Beekman (12103802)
Dokumenttyp: Text
Erscheinungsdatum: 2022
Schlagwörter: Medicine / Genetics / Molecular Biology / Pharmacology / Immunology / Developmental Biology / Cancer / Mental Health / Virology / short-acting β2-agonists / inhaled corticosteroids / SABINA (SABA use IN Asthma) / exacerbation / GINA
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-29253447
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.6084/m9.figshare.21732440.v2

The SABINA (SABA use IN Asthma) program was initiated to describe short-acting β2-agonists (SABA) prescription patterns and assess the impact of its over-prescription on exacerbation risk and asthma control. We evaluated SABA prescription patterns in patients with asthma in the Indian cohort of SABINA III. This multi-centre, observational, cross-sectional study included retrospective and real-time electronic data collection. Data were extracted from medical records of patients with asthma (aged >12 years) having >3 consultations with the same healthcare practitioners between March 2019 and January 2020. The data included prescriptions of SABA and other asthma treatments and over-the-counter (OTC) purchases of SABA. SABA prescriptions were categorized by the number of SABA canisters prescribed in the 12 months preceding the study visit. A total of 510 patients with asthma were included from specialist care (mean age 49.1 years; 57.65 females), with 8.2% classified with mild asthma and 91.8% with moderate-to-severe asthma. SABA as monotherapy and add-on to maintenance therapy was prescribed to 4.5% ( n = 23) and 44.9% ( n = 229) of patients, respectively. While ICS monotherapy and ICS/LABA were prescribed to 5.1% ( n = 26) and 93.3% ( n = 476) of patients, respectively. SABA was found to be over-prescribed (≥3 SABA canisters/year) among 23.9% of patients ( n = 122). Additionally, 8% of patients ( n = 41) purchased SABA OTC without prescription. Nearly one-fourth of patients with asthma in India were over-prescribed SABA. Educational programmes targeted at national and regional levels should be expanded to raise greater asthma awareness and encourage the adoption of guideline-directed asthma treatment plans among healthcare practitioners.